Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.078 AUD | 0.00% | +5.41% | +13.04% |
04-17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
04-17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+13.04% | 53.05M | |
-11.41% | 2.95B | |
+4.27% | 190M | |
-14.72% | 84.22M |
- Stock Market
- Equities
- NTI Stock
- News Neurotech International Limited
- Neurotech International Plans to Launch Phase Two Rett Syndrome Trial